L3VLUP
ProSign in

NBIX · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NBIXARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NBIX
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterNBIXARGX
Q3 202015 holders, $2.6bn8 holders, $3.6bn
Q4 202012 holders, $2.6bn7 holders, $4.1bn
Q1 20216 holders, $2.3bn8 holders, $4.1bn
Q2 20219 holders, $1.5bn9 holders, $4.6bn
Q3 20218 holders, $1.5bn8 holders, $4.5bn
Q4 202114 holders, $1.3bn9 holders, $5.3bn
Q1 202215 holders, $1.4bn8 holders, $5.3bn
Q2 202211 holders, $1.3bn13 holders, $6.5bn
Q3 202214 holders, $1.0bn14 holders, $5.3bn
Q4 202215 holders, $1.2bn13 holders, $5.5bn
Q1 202317 holders, $860m13 holders, $5.9bn
Q2 202316 holders, $1.1bn18 holders, $6.6bn
Q3 202324 holders, $1.4bn21 holders, $8.7bn
Q4 202321 holders, $1.6bn17 holders, $6.3bn
Q1 202419 holders, $1.5bn13 holders, $6.8bn
Q2 202417 holders, $1.4bn14 holders, $7.9bn
Q3 202411 holders, $1.2bn13 holders, $10.7bn
Q4 202414 holders, $2.0bn14 holders, $12.3bn
Q1 202514 holders, $1.6bn17 holders, $11.8bn
Q2 202516 holders, $2.5bn18 holders, $10.8bn
Q3 202515 holders, $2.6bn16 holders, $13.8bn
Q4 202521 holders, $2.8bn16 holders, $14.8bn
Q1 202617 holders, $2.9bn11 holders, $12.3bn
Q2 202610 holders, $2.7bn14 holders, $15.0bn
NBIX

Neurocrine Biosciences Inc

Holders
14
Reported value
$1.6bn
Buyers
10
Sellers
4

Breadth +6 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
17
Reported value
$11.8bn
Buyers
9
Sellers
9

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NBIX (10)

AQR Capital Management LLC, Bridgewater Associates LP, Dodge & Cox, Freestone Grove Partners LP, Hudson Bay Capital Management LP, PDT Partners LLC, Renaissance Technologies LLC, Soros Fund Management LLC, Walleye Capital LLC, Winton Group Ltd

Only ARGX (13)

Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Fidelity (FMR LLC), Holocene Advisors LP, Marshall Wace LLP, Millennium Management LLC, Moore Capital Management LP, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →